Answers are grounded in this paper and cite their sources.
Diabetes is a complication of cystic fibrosis (CF) that is of growing clinical importance. The recognition of diabetes complications in CF subjects (1) has emphasized the need for more accurate monitoring of glycemia. This is complicated by the many factors affecting glycemia in CF subjects, ranging from the consequences of malabsorption to the caloric burden of supplemental nutrition, as well as the metabolic effects of infection and drugs (2). The recent introduction of devices that provide a continuous glucose profile has revealed clinically relevant excursions in glycemia previously overlooked by conventional measures (3). They are able to provide the detailed glucose profile required in CF patients before and after an established diagnosis of cystic fibrosis-related diabetes (CFRD). Many of these new methods rely on sampling glucose levels in interstitial fluid and its …
No takes yet. Share an insight, caveat, or question.
Dobson et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: